Abstract
This study investigated the application of machine learning algorithms for survival prediction in bladder cancer patients undergoing cystectomy. We analyzed retrospective data from 370 patients, developing predictive models for disease-free survival (DFS), overall survival (OS), and cause of death. Multiple machine learning approaches were employed, including linear regression, random forests, gradient boosting, support vector machines, and neural networks. The models achieved mean absolute errors of 22-23 months for survival predictions and 66.67% accuracy in cause-of-death classification. Clinical T-stage emerged as the strongest predictor, while the Systemic Immune-Inflammation Index (SII) demonstrated a consistent negative correlation with survival outcomes. An unexpected positive correlation between age and survival was observed, possibly reflecting selection bias in surgical candidates. The study’s findings suggest that machine learning approaches, despite current limitations, offer promising tools for risk stratification in clinical trial design and patient allocation, though further refinement is needed for individual prognostication.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We collected retrospective data on patients with bladder cancer from Fondazione Policlinico Gemelli in Rome, Italy. Ethical approval was obtained from the institutional review board under protocol number 676-02.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All code used for this analysis is available at https://tinyurl.com/486yzuy4 to ensure the reproducibility of our results.
